Intech Investment Management LLC Boosts Position in DexCom, Inc. (NASDAQ:DXCM)

Intech Investment Management LLC boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 60.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 622,788 shares of the medical device company’s stock after buying an additional 235,458 shares during the period. DexCom accounts for approximately 1.4% of Intech Investment Management LLC’s portfolio, making the stock its 21st biggest holding. Intech Investment Management LLC’s holdings in DexCom were worth $48,434,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc acquired a new position in DexCom during the fourth quarter worth approximately $25,000. Private Trust Co. NA increased its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after buying an additional 245 shares during the period. Larson Financial Group LLC increased its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares during the period. Heck Capital Advisors LLC acquired a new position in DexCom during the fourth quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. acquired a new position in DexCom during the fourth quarter worth approximately $49,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent research reports. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Canaccord Genuity Group boosted their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Morgan Stanley boosted their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Stock Up 0.9 %

Shares of NASDAQ DXCM opened at $71.35 on Tuesday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a market capitalization of $27.88 billion, a PE ratio of 49.90, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm’s 50-day moving average is $83.82 and its two-hundred day moving average is $76.94.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 104,657 shares of company stock valued at $8,019,422. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.